Market Size and Growth
As per the Companion Animal Cardiac Drugs Market size analysis conducted by the BRI team, the companion animal cardiac drugs market is expected to record a CAGR of 9.28% from 2025 to 2034. In 2025, the market size was USD 2.38 Billion. By 2034, the valuation is anticipated to reach USD 5.28 Billion.
Overview
As per the industry experts at BRI, the global companion animal cardiac drugs market will witness a noticeable CAGR between 2025 and 2034. This could be attributed to the ongoing trend of hyperhumanization resulting in a rise in pet owner spending on veterinary care and the growing prevalence of cardiac conditions in the companion animals. The other driving factors include advancements with respect to veterinary cardiology, approvals of novel drugs like pimobendan for congestive heart failure, and enhanced diagnostic methods and tools. The market is also witnessing increased omnichannel distribution and e-Commerce for pharmaceuticals and a risen emphasis on preventive care.
Key Trends & Drivers
- Pet Humanization and Growing Incidences of Heart Disease to Spell Growth: With pets increasingly being viewed as family members, the owners are showing willingness regarding investment in their health, inclusive of specialized treatments for chronic ailments such as heart diseases. Growing number of companion animals, especially the older pets, are getting diagnosed with heart conditions like myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM).
- Pharmaceutical and Technological Innovations and Rise in Owners’ Awareness to Catalyze Growth: The development followed by approval of novel, effective cardiac drugs such as advancements in diagnostic technologies and pimobendan, does contribute to enhanced treatment outcomes. Rise in awareness amongst the pet owners regarding pet health and a rise in the number of veterinary specialists emphasize detecting and treating the cardiac conditions are also bolstering the market.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 2.38 Billion |
| Projected Market Size in 2034 | USD 5.28 Billion |
| Market Size in 2024 | USD 2.18 Billion |
| CAGR Growth Rate | 9.28% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Animal Type, Product, Indication, End-use, Distribution Channel and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
SWOT Analysis
- Strengths: Humanization of pets does ascertain sustained demand for high-class care, which includes specialized treatments for heart ailments. The ongoing R&D activities result in more effective and new cardiac therapies. Asia-Pacific is witnessing a notable increase in awareness resulting in pet ownership, thereby creating novel market segments.
- Weaknesses: Advanced cardiac drugs could prove to be expensive for the underdeveloped economies. Also, effective usage of such drugs needs specialized skills and knowledge from the vets. These could be some of the weaknesses witnessed by the companion animal cardiac drug market.
- Opportunities: Growing focus on preventive care does present opportunities to develop as well as market the cardiac-related medications for prevention of disease. There is a visible opportunity for developing specialized treatments like biologics for chronic conditions. Growing pet ownership in Asia-Pacific and LAMEA does offer a sizable potential for the market players.
- Threats: Economic slowdowns may compel the prospective pet owners to reduce spending on pet healthcare. Strict regulations and processes of approval for veterinary drugs could delay the launches of new products. Development of non-drug-based/alternative treatments could also pose as a threat.
List of the prominent players in the Companion Animal Cardiac Drugs Market:
- Boehringer Ingelheim International GmbH
- Ceva
- Elanco
- Virbac
- Zoetis
- Dechra Pharmaceuticals PLC
- Bimeda Corporate
- Biogénesis Bagó
- Merck & Co. Inc.
- Vetoquinol SA
- Others
The Companion Animal Cardiac Drugs Market is segmented as follows:
By Animal Type
- Dogs
- Cats
- Horses
By Product
- Pimobendan
- Spironolactone and Benazepril Hydrochloride
- Furosemide
By Indication
- Congestive Heart Failure
- Myocardial (Heart Muscle) Disease
- Arrhythmias
By End-use
- Veterinary Hospitals & Clinics
- Others
By Distribution Channel
- Hospital/Clinic Pharmacy
- Retail
- e-Commerce
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
[embedsocial_reviews id=”d4ae80cffae3d938f997111953699a733c8e6f99″]